Loading…
Reported covered position: Communications Director, Rep. David Young January 2017 - June 2017
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Speeding Therapy Access Today Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
S. 670/H.R. 1730, the Speeding Therapy Access Today (STAT) Act H.R. 482/ S. 350, the Newborn Screening Saves Lives Reauthorization Act H.R. 3783/S. 2013, the Medical Nutrition Equity Act of 2021 Cures 2.0 (not introduced yet)
Speeding Therapy Access Today Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act Cures 2.0 (not introduced)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ULTRAGENYX PHARMACEUTICAL via THE KPM GROUP DC LLC
2021 · fourth_quarter · Q4
H.R. 5376, the Build Back Better Act
Orphan Drug Tax Credit
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| CHIESI USA INC |
| 3 |
| 2020–2021 |
| GRITSTONE ONCOLOGY | 3 | 2020–2021 |
| OPIANT PHARMACEUTICALS | 3 | 2020–2021 |
| OVID THERAPEUTICS | 3 | 2020–2021 |
| ATAI LIFE SCIENCES N.V. | 2 | 2021 |
| ORPHAZYME US, INC. | 2 | 2020–2021 |
| PHARMAESSENTIA CORPORATION | 2 | 2021 |
| SANGAMO THERAPEUTICS, INC | 2 | 2020–2021 |
| SUMMIT THERAPEUTICS PLC | 2 | 2020 |
| THE BRAIN DONOR PROJECT | 2 | 2021 |
| ACCELERON PHARMA | 1 | 2021 |
| BIOAGILYTIX LABS, LLC | 1 | 2021 |
| NATIONAL BOARD FOR CERTIFIED COUNSELORS, INC. AND AFFILIATES | 1 | 2021 |
Speeding Therapy Access Today Act of 2021
Client: CHIESI USA, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, the Speeding Therapy Access Today (STAT) Act H.R. 2623, Camerons Law MACPAC Accelerated Approval Pathway Recommendations Cures 2.0 (not introduced yet)
Speeding Therapy Access Today Act of 2021
Client: SANGAMO THERAPEUTICS, INC · Firm: THE KPM GROUP DC LLC
Advancing Access to Precision Medicine Act (not introduced) H.R. 1730/S. 670, Speeding Therapy Access Today (STAT) Act Cures 2.0 (not introduced) PDUFA VII Reauthorization
Speeding Therapy Access Today Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act Cures 2.0 (not introduced)
Speeding Therapy Access Today Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 482/ S. 350, the Newborn Screening Saves Lives Speeding Therapy Access Today (STAT) Act - H.R. 1730/S. 670 Ensuring Lasting Smiles Act H.R. 1916/S. 754 HEART Act of 2020 - H.R. 7567 Reauthorization Act Cures 2.0
Speeding Therapy Access Today Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act
Speeding Therapy Access Today Act of 2021
Client: ORPHAZYME US, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, Speeding Therapy Access Today (STAT) Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
Speeding Therapy Access Today Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act Cures 2.0
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act Cures 2.0
H.R. 482/ S. 350, the Newborn Screening Saves Lives Speeding Therapy Access Today (STAT) Act - H.R. 1730/S. 670 Ensuring Lasting Smiles Act H.R. 1916/S. 754 HEART Act of 2020 - H.R. 7567 Reauthorization Act Cures 2.0
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act
H.R. 1730/S. 670, the Speeding Therapy Access Today (STAT) Act H.R. 2623, Camerons Law MACPAC Accelerated Approval Pathway Recommendations Cures 2.0 (not introduced yet)
H.R. 5376, the Build Back Better Act H.R. 6000, Cures 2.0 Act H.R. 2623, Camerons Law H.R. 482/S. 350, the Newborn Screening Saves Lives Reauthorization Act
Medical Nutrition Equity Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
S. 670/H.R. 1730, the Speeding Therapy Access Today (STAT) Act H.R. 482/ S. 350, the Newborn Screening Saves Lives Reauthorization Act H.R. 3783/S. 2013, the Medical Nutrition Equity Act of 2021 Cures 2.0 (not introduced yet)
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: ORPHAZYME US, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, Speeding Therapy Access Today (STAT) Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: RARE DISEASE COMPANY COALITION · Firm: THE KPM GROUP DC LLC
H.R. 5376, the Build Back Better Act H.R. 6000, Cures 2.0 Act H.R. 2623, Camerons Law H.R. 482/S. 350, the Newborn Screening Saves Lives Reauthorization Act
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
S. 670/H.R. 1730, the Speeding Therapy Access Today (STAT) Act H.R. 482/ S. 350, the Newborn Screening Saves Lives Reauthorization Act H.R. 3783/S. 2013, the Medical Nutrition Equity Act of 2021 Cures 2.0 (not introduced yet)
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: RARE DISEASE COMPANY COALITION · Firm: THE KPM GROUP DC LLC
H.R. 482/ S.350, the Newborn Screening Saves Lives Reauthorization Act MACPAC Accelerated Approval Pathway Recommendations
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 482/ S. 350, the Newborn Screening Saves Lives Speeding Therapy Access Today (STAT) Act - H.R. 1730/S. 670 Ensuring Lasting Smiles Act H.R. 1916/S. 754 HEART Act of 2020 - H.R. 7567 Reauthorization Act Cures 2.0
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act Cures 2.0 (not introduced)
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act Cures 2.0 (not introduced)
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: RARE DISEASE COMPANY COALITION · Firm: THE KPM GROUP DC LLC
H.R. 482/ S. 350, the Newborn Screening Saves Lives Reauthorization Act Build Back Better Act Cures 2.0
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act Cures 2.0
H.R. 5376, the Build Back Better Act
Inflation Reduction Act of 2022
Client: RARE DISEASE COMPANY COALITION · Firm: THE KPM GROUP DC LLC
H.R. 5376, the Build Back Better Act H.R. 6000, Cures 2.0 Act H.R. 2623, Camerons Law H.R. 482/S. 350, the Newborn Screening Saves Lives Reauthorization Act
Inflation Reduction Act of 2022
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 5376, the Build Back Better Act
H.R. 5376, the Build Back Better Act H.R. 6000, Cures 2.0 Act H.R. 2623, Camerons Law H.R. 482/S. 350, the Newborn Screening Saves Lives Reauthorization Act
Medical Nutrition Equity Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
S. 670/H.R. 1730, the Speeding Therapy Access Today (STAT) Act H.R. 482/ S. 350, the Newborn Screening Saves Lives Reauthorization Act H.R. 3783/S. 2013, the Medical Nutrition Equity Act of 2021 Cures 2.0 (not introduced yet)
Fairness in Orphan Drug Exclusivity Act
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
Fairness in Orphan Drug Exclusivity Act S. 250 Senate Finance Committee Drug Pricing Principles
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: RARE DISEASE COMPANY COALITION · Firm: THE KPM GROUP DC LLC
H.R. 5376, the Build Back Better Act H.R. 6000, Cures 2.0 Act H.R. 2623, Camerons Law H.R. 482/S. 350, the Newborn Screening Saves Lives Reauthorization Act
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
S. 670/H.R. 1730, the Speeding Therapy Access Today (STAT) Act H.R. 482/ S. 350, the Newborn Screening Saves Lives Reauthorization Act H.R. 3783/S. 2013, the Medical Nutrition Equity Act of 2021 Cures 2.0 (not introduced yet)
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 482/ S. 350, the Newborn Screening Saves Lives Speeding Therapy Access Today (STAT) Act - H.R. 1730/S. 670 Ensuring Lasting Smiles Act H.R. 1916/S. 754 HEART Act of 2020 - H.R. 7567 Reauthorization Act Cures 2.0
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: RARE DISEASE COMPANY COALITION · Firm: THE KPM GROUP DC LLC
H.R. 482/ S.350, the Newborn Screening Saves Lives Reauthorization Act MACPAC Accelerated Approval Pathway Recommendations
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act Cures 2.0 (not introduced)
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act Cures 2.0 (not introduced)
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: RARE DISEASE COMPANY COALITION · Firm: THE KPM GROUP DC LLC
H.R. 482/ S. 350, the Newborn Screening Saves Lives Reauthorization Act Build Back Better Act Cures 2.0
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act Cures 2.0
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: ORPHAZYME US, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, Speeding Therapy Access Today (STAT) Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
Speeding Therapy Access Today Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
S. 670/H.R. 1730, the Speeding Therapy Access Today (STAT) Act H.R. 482/ S. 350, the Newborn Screening Saves Lives Reauthorization Act H.R. 3783/S. 2013, the Medical Nutrition Equity Act of 2021 Cures 2.0 (not introduced yet)
Speeding Therapy Access Today Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act
Speeding Therapy Access Today Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 482/ S. 350, the Newborn Screening Saves Lives Speeding Therapy Access Today (STAT) Act - H.R. 1730/S. 670 Ensuring Lasting Smiles Act H.R. 1916/S. 754 HEART Act of 2020 - H.R. 7567 Reauthorization Act Cures 2.0
Speeding Therapy Access Today Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act Cures 2.0 (not introduced)
Speeding Therapy Access Today Act of 2021
Client: SANGAMO THERAPEUTICS, INC · Firm: THE KPM GROUP DC LLC
Advancing Access to Precision Medicine Act (not introduced) H.R. 1730/S. 670, Speeding Therapy Access Today (STAT) Act Cures 2.0 (not introduced) PDUFA VII Reauthorization
Speeding Therapy Access Today Act of 2021
Client: CHIESI USA, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, the Speeding Therapy Access Today (STAT) Act H.R. 2623, Camerons Law MACPAC Accelerated Approval Pathway Recommendations Cures 2.0 (not introduced yet)
Speeding Therapy Access Today Act of 2021
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act Cures 2.0 (not introduced)
Speeding Therapy Access Today Act of 2021
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act Cures 2.0
Speeding Therapy Access Today Act of 2021
Client: ORPHAZYME US, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, Speeding Therapy Access Today (STAT) Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act
H.R. 482/ S. 350, the Newborn Screening Saves Lives Speeding Therapy Access Today (STAT) Act - H.R. 1730/S. 670 Ensuring Lasting Smiles Act H.R. 1916/S. 754 HEART Act of 2020 - H.R. 7567 Reauthorization Act Cures 2.0
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act Cures 2.0
Helping Experts Accelerate Rare Treatments Act of 2020
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R. 482/ S. 350, the Newborn Screening Saves Lives Speeding Therapy Access Today (STAT) Act - H.R. 1730/S. 670 Ensuring Lasting Smiles Act H.R. 1916/S. 754 HEART Act of 2020 - H.R. 7567 Reauthorization Act Cures 2.0
Cancer Drug Parity Act of 2019
Client: SANGAMO THERAPEUTICS, INC · Firm: THE KPM GROUP DC LLC
Advancing Access to Precision Medicine Act (not introduced) H.R. 1730/S. 670, STAT Act Cures 2.0 (not introduced) PDUFA VII Reauthorization
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
Cancer Drug Parity Act of 2019
Client: SANGAMO THERAPEUTICS, INC · Firm: THE KPM GROUP DC LLC
Advancing Access to Precision Medicine Act (not introduced) H.R. 1730/S. 670, STAT Act Cures 2.0 (not introduced) PDUFA VII Reauthorization
Creating Hope Reauthorization Act
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
Creating Hope Reauthorization Act
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
Federal Employee Short-Term Disability Insurance Act of 2019
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
Federal Employee Short-Term Disability Insurance Act of 2019
Client: ZAMBON USA · Firm: THE KPM GROUP DC LLC
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
Federal Employee Short-Term Disability Insurance Act of 2019
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
Federal Employee Short-Term Disability Insurance Act of 2019
Client: OVID THERAPEUTICS · Firm: THE KPM GROUP DC LLC
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
To authorize the Secretary of Agriculture to maintain or replace certain facilities and structures for commercial recreation services at Smith Gulch in Idaho, and for other purposes.
Client: ORPHAZYME US, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
To authorize the Secretary of Agriculture to maintain or replace certain facilities and structures for commercial recreation services at Smith Gulch in Idaho, and for other purposes.
Client: ORPHAZYME US, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
S.3548/H.R. 748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act; COVID -19 Stimulus Package (domestic manufacturing)
Competitive Health Insurance Reform Act of 2019
Client: ORPHAZYME US, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
Competitive Health Insurance Reform Act of 2019
Client: ORPHAZYME US, INC. · Firm: THE KPM GROUP DC LLC
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
S.3548/H.R. 748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act; COVID -19 Stimulus Package (domestic manufacturing)
Pandemic Care for Burn Pits Exposure Act of 2020
Client: ZAMBON USA · Firm: THE KPM GROUP DC LLC
S.3868 - Pandemic Care for Burn Pits Exposure Act of 2020
Creating Hope Reauthorization Act
Client: AEGLEA BIOTHERAPEUTICS, INC. · Firm: THE KPM GROUP DC LLC
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
Creating Hope Reauthorization Act
Client: ULTRAGENYX PHARMACEUTICAL · Firm: THE KPM GROUP DC LLC
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
Creating Hope Reauthorization Act
Client: ALEXION PHARMACEUTICALS · Firm: THE KPM GROUP DC LLC
S.4010 - Creating Hope Reauthorization Act
Advancing Access to Precision Medicine Act (not introduced) H.R. 1730/S. 670, STAT Act Cures 2.0 (not introduced) PDUFA VII Reauthorization
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
Advancing Access to Precision Medicine Act (not introduced) H.R. 1730/S. 670, STAT Act Cures 2.0 (not introduced) PDUFA VII Reauthorization
2021 · fourth_quarter · Q4
H.R. 5376, the Build Back Better Act H.R. 6000, Cures 2.0 Act H.R. 2623, Camerons Law H.R. 482/S. 350, the Newborn Screening Saves Lives Reauthorization Act
Orphan Drug Tax Credit Accelerated Approval Pathway
Medicare Negotiation
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OPIANT PHARMACEUTICALS via THE KPM GROUP DC LLC
2021 · fourth_quarter · Q4
Substance Abuse Treatment
Filing targets: Substance Abuse & Mental Health Services Administration (SAMHSA)
MANNKIND CORPORATION via THE KPM GROUP DC LLC
2021 · fourth_quarter · Q4
H.R. 5376, the Build Back Better Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZAMBON USA via THE KPM GROUP DC LLC
2021 · third_quarter · Q3
Cures 2.0 (not introduced yet)
Burn Pits Legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via THE KPM GROUP DC LLC
2021 · third_quarter · Q3
Senate Finance Committee Drug Pricing Principles Orphan Drug Tax Credit
H.R. 482/ S. 350, the Newborn Screening Saves Lives Reauthorization Act Build Back Better Act Cures 2.0
Medicare Negotiation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BRAIN DONOR PROJECT via THE KPM GROUP DC LLC
2021 · third_quarter · Q3
NIH/NeuroBioBank Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MANNKIND CORPORATION via THE KPM GROUP DC LLC
2021 · third_quarter · Q3
CMS Medicare Part D Senior Savings Model
Filing targets: HOUSE OF REPRESENTATIVES
CHIESI USA, INC. via THE KPM GROUP DC LLC
2021 · third_quarter · Q3
FDA Inspections
H.R. 1730/S. 670, the Speeding Therapy Access Today (STAT) Act H.R. 2623, Camerons Law MACPAC Accelerated Approval Pathway Recommendations Cures 2.0 (not introduced yet)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AEGLEA BIOTHERAPEUTICS, INC. via THE KPM GROUP DC LLC
2021 · third_quarter · Q3
S. 670/H.R. 1730, the Speeding Therapy Access Today (STAT) Act H.R. 482/ S. 350, the Newborn Screening Saves Lives Reauthorization Act H.R. 3783/S. 2013, the Medical Nutrition Equity Act of 2021 Cures 2.0 (not introduced yet)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ULTRAGENYX PHARMACEUTICAL via THE KPM GROUP DC LLC
2021 · third_quarter · Q3
H.R. 482/ S. 350, the Newborn Screening Saves Lives Speeding Therapy Access Today (STAT) Act - H.R. 1730/S. 670 Ensuring Lasting Smiles Act H.R. 1916/S. 754 HEART Act of 2020 - H.R. 7567 Reauthorization Act Cures 2.0
Fairness in Orphan Drug Exclusivity Act S. 250 Senate Finance Committee Drug Pricing Principles
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via THE KPM GROUP DC LLC
2021 · second_quarter · Q2
H.R. 482/ S.350, the Newborn Screening Saves Lives Reauthorization Act MACPAC Accelerated Approval Pathway Recommendations
Senate Finance Committee Drug Pricing Principles
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL BOARD FOR CERTIFIED COUNSELORS AND AFFILIATES, INC. via THE KPM GROUP DC LLC
2021 · fourth_quarter · RR
Adding mental health counselors as an eligible provider of psychotherapy services under Medicare Part B Increase hiring of mental health counselors by the Department of Veteran's Affairs Increasing funding for SAMHSA's Minority Fellowship Program Ensuring the inclusion of counselors in telehealth measures
Adding mental health counselors as an eligible provider of psychotherapy services under Medicare Part B Increase hiring of mental health counselors by the Department of Veteran's Affairs Increasing funding for SAMHSA's Minority Fellowship Program Ensuring the inclusion of counselors in telehealth measures
RARE DISEASE COMPANY COALITION via THE KPM GROUP DC LLC
2021 · first_quarter · RR
Treatment of rare diseases.
ATAI LIFE SCIENCES N.V. via THE KPM GROUP DC LLC
2021 · second_quarter · 2A
Coverage and Reimbursement for Mental Health Services
DEA Restrictions on Psychedelics
Filing targets: HOUSE OF REPRESENTATIVES
ATAI LIFE SCIENCES N.V. via THE KPM GROUP DC LLC
2021 · second_quarter · RR
DEA Restrictions on Psychedelics; Coverage and Reimbursement for Mental Health Services
DEA Restrictions on Psychedelics; Coverage and Reimbursement for Mental Health Services
THE BRAIN DONOR PROJECT via THE KPM GROUP DC LLC
2021 · second_quarter · RR
Discuss mission to raise awareness for brain donation; increased funding for NIH
PHARMAESSENTIA CORPORATION via THE KPM GROUP DC LLC
2021 · second_quarter · 2A
FDA Foreign Inspections Backlog
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MANNKIND CORPORATION via THE KPM GROUP DC LLC
2021 · second_quarter · 2A
CMS Medicare Part D Senior Savings Model
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZAMBON USA via THE KPM GROUP DC LLC
2021 · second_quarter · Q2
Introductory Meeting; Burn Pits Legislation
Filing targets: HOUSE OF REPRESENTATIVES
ULTRAGENYX PHARMACEUTICAL via THE KPM GROUP DC LLC
2021 · second_quarter · Q2
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AEGLEA BIOTHERAPEUTICS, INC. via THE KPM GROUP DC LLC
2021 · second_quarter · Q2
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act Cures 2.0 (not introduced)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOAGILYTIX LABS, LLC via THE KPM GROUP DC LLC
2021 · first_quarter · RR
Cures 2.0, sitting on advisory committees/panels, FDA reform
MANNKIND CORPORATION via THE KPM GROUP DC LLC
2021 · first_quarter · Q1
PPE Production through DPA
CMS Medicare Part D Senior Savings Model
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ORPHAZYME US, INC. via THE KPM GROUP DC LLC
2021 · first_quarter · Q1
H.R. 1730/S. 670, Speeding Therapy Access Today (STAT) Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
Filing targets: SENATE
SANGAMO THERAPEUTICS, INC via THE KPM GROUP DC LLC
2021 · first_quarter · Q1
Advancing Access to Precision Medicine Act (not introduced) H.R. 1730/S. 670, Speeding Therapy Access Today (STAT) Act Cures 2.0 (not introduced) PDUFA VII Reauthorization
Filing targets: HOUSE OF REPRESENTATIVES
ACCELERON PHARMA via THE KPM GROUP DC LLC
2021 · first_quarter · RR
drug pricing, rare disease issues, Medicare Part D
drug pricing, rare disease issues, Medicare Part D
PHARMAESSENTIA CORPORATION via THE KPM GROUP DC LLC
2021 · second_quarter · RR
FDA inspections
GRITSTONE ONCOLOGY via THE KPM GROUP DC LLC
2021 · first_quarter · Q1
COVID-19 vaccine development - manufacturing scale-up assistance
Filing targets: SENATE
AEGLEA BIOTHERAPEUTICS, INC. via THE KPM GROUP DC LLC
2021 · first_quarter · Q1
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act Cures 2.0 (not introduced)
Drug Pricing
Filing targets: HOUSE OF REPRESENTATIVES
OVID THERAPEUTICS via THE KPM GROUP DC LLC
2021 · first_quarter · Q1
Pharma M&A
Filing targets: HOUSE OF REPRESENTATIVES
ULTRAGENYX PHARMACEUTICAL via THE KPM GROUP DC LLC
2021 · first_quarter · Q1
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act H.R. 1916/S.754, Ensuring Lasting Smiles Act Cures 2.0
Drug pricing
Filing targets: HOUSE OF REPRESENTATIVES
MANNKIND CORPORATION via THE KPM GROUP DC LLC
2020 · fourth_quarter · RR
CMS Senior Savings Model and PPE Production through DPA
CMS Senior Savings Model and PPE Production through DPA
SANGAMO THERAPEUTICS, INC via THE KPM GROUP DC LLC
2020 · fourth_quarter · RR
Advancing Access to Precision Medicine Act (not introduced) H.R. 1730/S. 670, STAT Act Cures 2.0 (not introduced) PDUFA VII Reauthorization
Advancing Access to Precision Medicine Act (not introduced) H.R. 1730/S. 670, STAT Act Cures 2.0 (not introduced) PDUFA VII Reauthorization
ORPHAZYME US, INC. via THE KPM GROUP DC LLC
2020 · fourth_quarter · RR
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act
CHIESI USA, INC. via THE KPM GROUP DC LLC
2020 · fourth_quarter · Q4
Priority Review Voucher Program; FDA international inspections
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via THE KPM GROUP DC LLC
2020 · fourth_quarter · RR
Priority Review Voucher Program; FDA international inspections
ZAMBON USA via THE KPM GROUP DC LLC
2020 · fourth_quarter · Q4
S.3868 - Pandemic Care for Burn Pits Exposure Act of 2020
Filing targets: SENATE
OVID THERAPEUTICS via THE KPM GROUP DC LLC
2020 · fourth_quarter · Q4
Priority Review Voucher Program
Filing targets: SENATE
AEGLEA BIOTHERAPEUTICS, INC. via THE KPM GROUP DC LLC
2020 · third_quarter · Q3
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
Drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS via THE KPM GROUP DC LLC
2020 · third_quarter · Q3
S.4010 - Creating Hope Reauthorization Act
Filing targets: SENATE
ZAMBON USA via THE KPM GROUP DC LLC
2020 · third_quarter · Q3
Drug pricing
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OVID THERAPEUTICS via THE KPM GROUP DC LLC
2020 · third_quarter · Q3
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
Drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ULTRAGENYX PHARMACEUTICAL via THE KPM GROUP DC LLC
2020 · third_quarter · Q3
H.R.4493 - Federal Employee Short-Term Disability Insurance Act of 2019 S.4010/H.R. 4439 - Creating Hope Reauthorization Act
Drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRITSTONE ONCOLOGY via THE KPM GROUP DC LLC
2020 · second_quarter · Q2
Biomedical Advanced Research and Development Authority (BARDA) engagement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AEGLEA BIOTHERAPEUTICS, INC. via THE KPM GROUP DC LLC
2020 · second_quarter · Q2
Meetings on Priority Review Vouchers and Biomedical Advanced Research and Development Authority (BARDA) Engagement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUMMIT THERAPEUTICS PLC via THE KPM GROUP DC LLC
2020 · second_quarter · Q2
S.3548/H.R. 748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act; COVID -19 Stimulus Package (domestic manufacturing)
Filing targets: SENATE
GRITSTONE ONCOLOGY via THE KPM GROUP DC LLC
2020 · second_quarter · RR
Biomedical Advanced Research and Development Authority (BARDA) engagement
AEGLEA BIOTHERAPEUTICS, INC. via THE KPM GROUP DC LLC
2020 · second_quarter · RR
Priority Review Vouchers and Biomedical Advanced Research and Development Authority (BARDA) engagement
SUMMIT THERAPEUTICS PLC via THE KPM GROUP DC LLC
2020 · second_quarter · RR
COVID -19 Stimulus Package (domestic manufacturing)
ZAMBON USA via THE KPM GROUP DC LLC
2020 · second_quarter · Q2
Orphan Drug Tax Credit, Rare/Orphan Drug issues, 21st Century Cures, Coverage Decisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), SENATE
OPIANT PHARMACEUTICALS via THE KPM GROUP DC LLC
2020 · second_quarter · Q2
Opioids/FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS via THE KPM GROUP DC LLC
2020 · second_quarter · Q2
Medicare Policy and Reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ULTRAGENYX PHARMACEUTICAL via THE KPM GROUP DC LLC
2020 · second_quarter · Q2
New Born Screening Act, Drug Pricing, Priority Review Voucher Program
Filing targets: SENATE, White House Office
ZAMBON USA via THE KPM GROUP DC LLC
2020 · first_quarter · Q1
Orphan Drug Tax Credit, Rare/Orphan Drug issues, 21st Century Cures
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ULTRAGENYX PHARMACEUTICAL via THE KPM GROUP DC LLC
2020 · first_quarter · Q1
New Born Screening, Orphan Drug Act, FDA
Filing targets: Centers For Medicare and Medicaid Services (CMS), SENATE, White House Office
OPIANT PHARMACEUTICALS via THE KPM GROUP DC LLC
2020 · first_quarter · Q1
Opioids/FDA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS via THE KPM GROUP DC LLC
2020 · first_quarter · Q1
Medicare Policy and Reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS)